PHVS · Nasdaq · CIK 0001830487

Pharvaris N.V.

Pharvaris N.V.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 13, 2026. Its EDGAR record lists 55 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-EUR 175.7M
Form 4 filings on record, past 12 months
55

Company overview

Legal name (as filed)
Pharvaris N.V.
Ticker
PHVS
SEC Central Index Key (CIK)
0001830487
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
LEIDEN
State or country of incorporation
Netherlands
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1918 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Pharvaris N.V.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-EUR 42.7MFY2021-EUR 76.3MFY2022-EUR 100.9MFY2023-EUR 134.2MFY2024-EUR 175.7MFY2025
PHVS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-EUR 42.7M-EUR 76.3M-EUR 100.9M-EUR 134.2M-EUR 175.7M
Diluted EPS-EUR 1.40-EUR 2.27-EUR 2.63-EUR 2.48-EUR 2.97
Total assetsEUR 212.1MEUR 167.7MEUR 398.7MEUR 291.4MEUR 301.5M
Cash and equivalentsEUR 209.4MEUR 161.8MEUR 391.2MEUR 280.7MEUR 291.7M

XBRL tags used: netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

PHVS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Apr 2, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Pharvaris N.V., by form type:

4 ×20144 ×176-K ×2144/A ×1
PHVS recent filings
FiledFormWhat it isOriginal
Oct 13, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 11, 2026Document · Index
Sep 25, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 23, 2026Document · Index
Sep 24, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 22, 2026Document · Index
Sep 24, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 22, 2026Document · Index
Sep 23, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 22, 2026144/A144/ADocument · Index
Sep 22, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026Document · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026Document · Index
Sep 16, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 14, 2026Document · Index
Sep 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 11, 2026Document · Index
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 14, 2026Document · Index
Sep 14, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 14, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 9, 2026Document · Index
Sep 10, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 9, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 9, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Aug 18, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026Document · Index
Aug 14, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

55 Form 4 filings appear in Pharvaris N.V.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001830487 and XBRL company facts. Pharvaris N.V. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.